Atherosclerotic risk among children taking antiepileptic drugs

Pharmacological Reports

Volumn 61, Issue 3, 2009, Pages 411-423

  Jakubus, Tomasz ^a   Michalska Jakubus, Małgorzata ^b   Łukawski, Krzysztof ^a   Janowska, Agnieszka ^a   Czuczwar, Stanisław J ^a,b  

^a INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Antiepileptic drugs; Atherosclerosis; Epileptic children; Homocysteine; Lipids

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXCARBAZEPINE; PHENOBARBITAL; THYROTROPIN; TRIACYLGLYCEROL; VALPROIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CYANOCOBALAMIN DEFICIENCY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPILEPSY; ERYTHROCYTE LEVEL; FOLIC ACID BLOOD LEVEL; FOLIC ACID ERYTHROCYTE LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HEART INFARCTION; HORMONE RESPONSE; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; LONG TERM CARE; MENTAL DISEASE; NONHUMAN; PREVALENCE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; THYROID DISEASE; THYROID HORMONE BLOOD LEVEL; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICONVULSANTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHILD; EPILEPSY; FOLIC ACID; HUMANS; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIAS; HYPOTHYROIDISM; LIPOPROTEIN(A); RISK FACTORS; VITAMIN B DEFICIENCY;

EID: 67651152714     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70082-9     Document Type: Review

References (140)

1. Annegers JF, Hauser WA, Shirts SB: Heart disease mortality and morbidity in patients with epilepsy. Epilepsia, 1984, 25, 699-704.
2. Apeland T, Mansoor MA, Pentieva K, McNulty H, Seljeflot I, Strandjord RE: The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs. Epilepsy Res, 2002, 51, 237-247.
3. Asami T, Ciomartan T, Uchiyama M: Thyroxine inversely regulates serum intermediate density lipoprotein levels in children with congenital hypothyroidism. Pediatr Int, 1999, 41, 266-269.
4. Attilakos A, Garoufi A, Voudris K, Mastroyianni S, Fotinou A, Papadimitriou DT, Gavalakis N et al.: Thyroid dysfunction associated with increased low-density lipoprotein cholesterol in epileptic children treated with carbamazepine monotherapy: A causal relationship? Eur J Paediatr Neurol, 2007, 11, 358-361.
5. Aynaci FM, Orhan F, Örem A, Yildirmis S, Gedik Y: Effect of antiepileptic drugs on plasma lipoprotein (a) and other lipid levels in childhood. J Child Neurol, 2001, 16, 367-369.
6. Bentsen KD, Gram L, Veje A: Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate: a controlled study. Acta Neurol Scand, 1983, 67, 235-241.
7. Berenson GS, Srinivasan SR, Bao W, Newman WP 3rd, Tracy RE, Wattigney WA: Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med, 1998, 338, 1650-1656.
8. Berg K: A new serum type system in man - The Lp system. Acta Pathol Microbiol Scand, 1963, 59, 369-382.
9. Biondi B, Klein I: Hypothyroidism as a risk factor for cardiovascular disease. Endocrine, 2004, 24, 1-13.
10. Br-dsamswig S, Kerksiek A, Sudhop T, Luers C, Von Bergmann K, Berthold HK: Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am J Physiol Heart Circ Physiol, 2002, 282, 704-716.
11. Brämswig S, Sudhop T, Luers C, von Bergmann K, Berthold HK: Lipoprotein (a) concentration increases during treatment with carbamazepine. Epilepsia, 2003, 44, 457-460.
12. Cansu A, Serdaroǧlu A, Camurdan O, Hirfanoǧlu T, Bideci A, Gücüyener K: The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia, 2006, 47, 1855-1859.
13. Caparevic Z, Bojkovic G, Stojanovic D, Ilic V: Dyslipidemia and subclinical hypothyroidism. Med Pregl, 2003, 56, 276-280.
14. Castro-Gago M, Novo-Rodríguez MI, Blanco-Barca MO, Urisarri-Ruíz de Cortázar A, Rodríguez-García J, Rodríguez-Segade S, Eirís-Puñal J: Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J Child Neurol, 2006, 21, 48-53.
15. Castro-Gago M, Novo-Rodríguez MI, Gómez-Lado C, Rodríguez-García J, Rodríguez-Segade S, Eirís-Puñal J: Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs. Pediatr Neurol, 2007, 37, 426-430.
16. Chanarin I, Laidlaw J, Loughridge Lavinia W, Mollin DL: Megaloblastic anaemia due to phenobarbitone. The convulsant action of therapeutic doses of folic acid. Br Med J, 1960, 09, 1099-1102.
17. Chern CL, Huang RFS, Chen YH, Cheng JT, Liu TZ: Folate deficiency-induced oxidative stress and apoptosis are mediated via homocysteine-dependent overproduction of hydrogen peroxide and enhanced activation of NF-kappaB in human Hep G2 cells. Biomed Pharmacother, 2001, 55, 434-442.
18. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I: Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med, 1991, 324, 1149-1155.
19. Cohen-Aubart F, Jublanc C, Chiche F, Bruckert E: Subclinical hypothyroidism: a cardiovascular risk factor? Arch Mal Coeur Vaiss, 2007, 100, 213-216.
20. Connell JM, Rapaport WG, Gordon S, Brodie MJ: Changes in circulating thyroid hormones during short-term hepatic enzyme induction with carbamazepine. Eur J Clin Pharmacol, 1984, 26, 453-456.
21. Dasheiff RM: Sudden unexpected death in epilepsy: a series from an epilepsy surgery program and speculation on the relationship to sudden cardiac death. J Clin Neurophysiol, 1991, 8, 216-222.
22. Dastur DK, Dave UP: Effect of prolonged anticonvulsant medication in epileptic patients: serum lipids, vitamins B6, B12, and folic acid, proteins, and fine structure of liver. Epilepsia, 1987, 28, 147-159.
23. De Chadarévian J, Legido A, Miles D, Katsetos C: Epilepsy, atherosclerosis, myocardial infarction, and carbamazepine. J Child Neurol, 2003, 18, 150-151.
24. De Juan J, Crespo M, Braga S: Efectos del fenobarbital, ácido valproico y carbamacepina sobre lípidos y lipoproteínas séricas en población infanto-juvenil. An Esp Pediatr, 1996, 44, 133-138.
25. Demircioǧlu S, Soylu A, Dirik E: Carbamazepine and valproic acid: effects on the serum lipids and liver functions in children. Pediatr Neurol, 2000, 23, 142-146.
26. Dörr M, Völzke H: Cardiovascular morbidity and mortality in thyroid dysfunction. Minerva Endocrinol, 2005, 30, 199-216.
27. Duntas LH, Wartofsky L: Cardiovascular Risk and subclinical hypothyroidism: Focus on Lipids and New Emerging Risk Factors. What Is the Evidence? Thyroid, 2007, 17, 1075-1084.
28. Eirís J, Novo-Rodríguez MI, Del Río M, Meseguer P, Del Río MC, Castro-Gago M: The effects on lipid and apolipoprotein serum levels of long-term carbamazepine, valproic acid and phenobarbital therapy in children with epilepsy. Epilepsy Res, 2000, 41, 1-7.
29. Eirís JM, Lojo S, Del Río MC, Novo I, Bravo M, Pavón P, Castro-Gago M: Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology, 1995, 45, 1155-1157.
30. Eirís-Puñal J, Del Río-Garma M, Del Río-Garma MC, Lojo-Rocamonde S, Novo-Rodríguez I, Castro-Gago M: Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia, 1999, 40, 1761-1766.
31. Elliott JO, Jacobson MP, Haneef Z: Cardiovascular risk factors and homocysteine in epilepsy. Epilepsy Res, 2007, 76, 113-123.
32. Ericsson UB, Bjerre I, Forsgren M, Ivarsson SA: Thyroglobulin and thyroid hormones in patients on long-term treatment with phenytoin, carbamazepine, and valproic acid. Epilepsia, 1985, 26, 594-596.
33. Finkelstein JD: Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost, 2000, 26, 219-225.
34. Fischel H, Knöpfle G: Effects of anticonvulsant drugs on thyroid hormones in epileptic children. Epilepsia, 1978, 19, 323-336.
35. Födinger M, Buchmayer H, Sunder-Plassmann G: Molecular genetics of homocysteine metabolism. Miner Electrolyte Metab, 1999, 25, 269-278.
36. Födinger M, Hörl WH, Sunder-Plassmann G: Molecular biology of 5,10-methylenetetrahydrofolate reductase. J Nephrol, 2000, 13, 20-33.
37. Franzoni E: Topiramate: effects on serum lipids and lipoproteins levels in children. Eur J Neurol, 2007, 14, 1334-1337.
38. Franzoni E, Govoni M, D'Addato S, Gualandi S, Sangiorgi Z, Descovich GC, Salvioli GP: Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children receiving antiepileptic drugs. Epilepsia, 1992, 33, 932-935.
39. Franzoni E, Marchiani V, Cecconi I, Moscano FC, Gualandi S, Garone C, Sarajlija J, Malaspina E:: Preliminary report on effects of oxcarbazepine-treatment on serum lipid levels in children. Eur J Neurol, 2006, 13, 1389-1391.
40. Fröscher W, Maier V, Laage M, Wolfersdorf M, Straub R, Rothmeier J, Steinert T et al.: Folate deficiency, anticonvulsant drugs, and psychiatric morbidity. Clin Neuropharmacol, 1995, 18, 165-182.
41. Gaitatzis A, Carroll K, Majeed A, W Sander J: The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia, 2004, 45, 1613-1622.
42. Geda G, Caksen H, Içaǧasioǧlu D: Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy. Acta Neurol Belg, 2002, 102, 122-126.
43. Girdwood RH, Lenham JAR: Megaloblastic anaemia during primidone therapy. Br Med J, 1956, 1, 146-147.
44. Glass CK, Witztum JL: Atherosclerosis: the road ahead. Cell, 2001, 104, 503-516.
45. Hamed S, Hamed E, Hamdy R, Nabeshima T: Vascular risk factors and oxidative stress as independent predictors of asymptomatic atherosclerosis in adult patients with epilepsy. Epilepsy Res, 2007, 74, 183-192.
46. Hamed S, Hamed E, Kandil M, El-Shereef H, Abdellah M, Omar H: Serum thyroid hormone balance and lipid profile in patients with epilepsy. Epilepsy Res, 2005, 66, 173-183.
47. Hamed SA, Nabeshima T: The high atherosclerotic risk among epileptics: the atheroprotective role of multivitamins. J Pharmacol Sci, 2005, 98, 340-353.
48. Heinecke JW, Kawamura M, Suzuki L, Chait A: Oxidation of low-density lipoprotein by thiols: superoxidedependent and -independent mechanisms. J Lipid Res. 1993, 34, 2051-2061.
49. Heinecke JW, Rosen H, Suzuki LA, Chait A: The role of sulfur-containing amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem, 1987, 262, 10098-100103.
50. Heldemberg D, Harel S, Holtzman M, Levtow O, Tamir I: The effect of chronic anticonvulsant therapy on serum lipids and lipoproteins in epileptic children. Neurology, 1983, 33, 510-513.
51. Herbert V: Development of human folate deficiency. In: Folic Acid Metabolism in Health and Disease. Eds. Picciano MF, Stokstad ELR, Gregory JF III, New York, Wiley-Liss, 1990, 195-210.
52. Hirfanoglu T, Serdaroglu A, Camurdan O, Cansu A, Bideci A, Cinaz P, Gucuyener K: Thyroid function and volume in epileptic children using carbamazepine, oxcarbazepine and valproate. Pediatr Int, 2007, 49, 822-826.
53. Ho PI, Ashline D, Dhitavat S, Ortiz D, Collins SC, Shea TB: Folate deprivation induces neurodegeneration: roles of oxidative stress and increased homocysteine. Neurobiol Dis, 2003, 14, 32-42.
54. Hobbs HH, White AL: Lipoprotein (a) intrigues and insights. Curr Opin Lipidol, 1999, 10, 225-236.
55. Hoffbrand AV, Necheles T: Mechanism of folate deficiency in patients receiving phenytoin. Lancet, 1968, 7, 528-530.
56. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: metaanalysis of randomised trials. BMJ, 1998, 316, 894-898.
57. Hoppichler F, Sandholzer C, Moncayo R, Utermann G, Kraft HG: Thyroid hormone (fT4) reduces lipoprotein (a) plasma levels. Atherosclerosis, 1995, 115, 65-71.
58. Horie A, Suga T: Enhacement of peroxisomal beta-oxidation in the liver of rats and mice treated with valproic acid. Biochem Pharmacol, 1985, 34, 1357-1362.
59. Huemer M, Ausserer B, Graninger G, Hubmann M, Huemer C, Schlachter K, Tscharre A et al.: Hyperhomocysteinemia in children treated with antiepileptic drugs is normalized by folic acid supplementation. Epilepsia, 2005, 46, 1677-1683.
60. Huesca-Gomez C, Franco M, Luc G, Montano LF, Masso F, Posadas-Romero C, Pérez-Méndez O: Chronic hypothyroidism induces abnormal structure of highdensity lipoproteins and impaired kinetics of apolipoprotein A-I in the rat. Metabolism, 2002, 51, 443-450.
61. Ibbotson RN, Dilena BA, Horwood JM: Studies on deficiency and absorption of folates in patients on anticonvulsant drugs. Australas Ann Med, 1967, 16, 144-150.
62. Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllylä VV: Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol, 1996, 39, 579-584.
63. Isojärvi JIT, Pakarinen AJ, Myllylä VV: Thyroid function in epileptic patients treated with carbamazepine. Arch Neurol, 1989, 46, 1175-1178.
64. Isojarvi JI, Pakarinen AJ, Rautio A, Pelkonen O, Myllyla VV: Liver enzyme induction and serum lipid levels after replacement of carbamazepine with oxcarbazepine. Epilepsia, 1994, 35, 1217-1220.
65. Isojarvi JI, Turkka J, Pakarinen AJ, Kotila M, Rattya J, Myllyla VV: Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy. Epilepsia, 2001, 42, 930-934.
66. Jensen ON, Olesen OV: Folic acid and anticonvulsive drugs. Arch Neurol, 1969, 21, 208-214.
67. Kahaly GJ: Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid, 2000, 10, 665-679.
68. Karabiber H, Sonmezgoz E, Ozerol E, Yakinci C, Otlu B, Yologlu S: Effects of valproate and carbamazepine on serum levels of homocysteine, vitamin B12, and folic acid. Brain Dev, 2003, 25, 113-115.
69. Kaste M, Muuronen A, Nikkilä EA, Neuvonen PJ: Increase of low serum concentrations of high-density lipoprotein (HDL) cholesterol in TIA-patients treated with phenytoin. Stroke, 1983, 14, 525-530.
70. Kim JY, Lee HW: Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia, 2007, 48, 1366-1370.
71. Kirimi E, Karasalihoglu S, Boz A: Thyroid functions in children under long-term administration of antiepileptic drugs. Eastern J Med, 1999, 4, 23-26.
72. Kishi T, Fujita N, Eguchi T, Ueda K: Mechanism for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci, 1997, 145, 109-112.
73. Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M, Moes N et al.: Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res, 1997, 38, 1755-1763.
74. Kubová H, Folbergrová J, Mares P: Seizures induced by homocysteine in rats during ontogenesis. Epilepsia, 1995, 36, 750-756.
75. Kung AW, Pang RW, Janus ED: Elevated serum lipoprotein(a) in subclinical hypothyroidism. Clin Endocrinol (Oxf), 1995, 43, 445-449.
76. Lambie DG, Johnson RH: Drugs and folate metabolism. Drugs, 1985, 30, 145-155.
77. Lewis DP, Van Dyke DC, Willhite LA, Stumbo PJ, Berg MJ: Phenytoin-folic acid interaction. Ann Pharmacother, 1995, 29, 726-735.
78. Li X, Breteler MMB, Bruyne MC de, Meinardi H, Hauser WA, Hofman A: Vascular determinants of epilepsy: the Rotterdam Study. Epilepsia, 1997, 38, 1216-1220.
79. Luboshitzky R, Aviv A, Herer P, Lavie L: Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid, 2002, 12, 421-425.
80. Luoma PV, Myllylä VV, Hokkanen E: Relationship between plasma high-density lipoprotein cholesterol and anticonvulsant levels in epileptics. J Cardiovasc Pharmacol, 1982, 4, 1024-1027.
81. Luoma PV, Myllyla VV, Sotaniemi EA, Lehtinen IA, Hokkanen EJ: Plasma high-density lipoprotein cholesterol in epileptics treated with various anticonvulsants. Eur Neurol, 1980, 19, 67-72.
82. Marangos PJ, Loftus T, Wiesner J, Lowe T, Rossi E, Browne CE, Gruber HE: Adenosinergic modulation of homocysteine-induced seizures in mice. Epilepsia, 1990, 31, 239-246.
83. Maxwell JD, Hunter J, Stewart DA, Ardeman S, Williams R: Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction? Br Med J, 1972, 29, 297-299.
84. Mikati MA, Tarabay H, Khalil A, Rahi AC, El Banna D, Najjar S: Risk factors for development of subclinical hypothyroidism during valproic acid therapy. J Pediatr, 2007, 151, 178-181.
85. Miller AA, Sawyer DA, Roth B: Lamotrigine. In: New Anticonvulsant Drugs. Eds. Meldrum BS, Porter RP, John Libbey, London, 1986, 165-177.
86. Moat SJ: Plasma total homocysteine: instigator or indicator of cardiovascular disease? Ann Clin Biochem, 2008, 45, 345-348.
87. Morgan SL, Baggott JE, Lee JY, Alarcon GS: Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: Implications for cardiovascular disease prevention. J Rheumatol, 1998, 25, 441-446.
88. Morrell MJ, Isojärvi J, Taylor AE, Dam M, Ayala R, Gomez G, O'Neill F et al.: Higher androgens and weight gain with valproate compared with lamotrigine for epilepsy. Epilepsy Res, 2003, 54, 189-199.
89. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G et al.: The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet, 1985, 37, 1-31.
90. Muuronen A, Kaste M, Nikkilä EA, Tolppanen EM: Mortality from ischaemic heart disease among patients using anticonvulsive drugs: a case-control study. Br Med J, 1985, 23, 1481-1483.
91. Nakken KO, Kornstad S: Do males 30-50 years of age with chronic epilepsy and on long-term anticonvulsant medication have lower-than-expected risk of developing coronary heart disease? Epilepsia, 1998, 39, 326-330.
92. Nilsson L, Tomson T, Farahmand BY, Diwan V, Persson PG: Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia, 1997, 38, 1062-1068.
93. Ono H, Sakamoto A, Eguchi T, Fujita N, Nomura S, Ueda H, Sakura N, Ueda K: Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism, 1997, 46, 959-962.
94. Ono H, Sakamoto A, Mizoguchi N, Sakura N: The C677T mutation in the methylenetetrahydrofolate reductase gene contributes to hyperhomocysteinemia in patients taking anticonvulsants. Brain Dev, 2002, 24, 223-226.
95. Palmieri EA, Fazio S, Lombardi G, Biondi B: Subclinical hypothyroidism and cardiovascular risk: a reason to treat? Treat Endocrinol, 2004, 3, 233-244.
96. Patsalos PN, Zakrzewska JM, Elyas AA: Dose dependent enzyme induction by oxcarbazepine? Eur J Clin Pharmacol, 1990, 39, 187-188.
97. Pesic M, Antic S, Kocic R, Radojkovic D, Radenkovic S: Cardiovascular risk factors in patients with subclinical hypothyroidism. Vojnosanit Pregl, 2007, 64, 749-752
98. Reddy MN: Effect of anticonvulsant drugs on plasma total cholesterol, high-density lipoprotein cholesterol, and apolipoproteins A and B in children with epilepsy. Proc Soc Exp Biol Med, 1985, 180, 359-363.
99. Reynolds EH: Chronic antiepileptic toxicity. A review. Epilepsia, 1975, 16, 319-352.
100. Riba R, Nicolaou A, Troxler M, Homer-Vaniasinkam S, Naseem KM: Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis, 2004, 175, 69-75.
101. Ridker PM, Hennekens CH, Stampfer MJ: A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA, 1993, 270, 2195-2199.
102. Rootwelt K, Ganes T, Johannessen SI: Effect of carbamazepine, phenytoin and phenobarbitone on serum levels of thyroid hormones and thyrotropin in humans. Scand J Clin Lab Invest, 1978, 38, 731-736.
103. Rousso I, Pharmakiotis A, Gatzola M, Karatza E, Tourkantonis A: Effects of phenobarbital, diphenylhydantoin and carbamazepine on thyroid function in epileptic children. Acta Endocrinol, Suppl 1984, 265, 48-49.
104. Schreiner PJ, Wu KK, Malinow MR, Nieto FJ, Heiss G: Plasma homocyst(e)ine and hemostasis: the ARIC Study. Circulation. 1994, 89, 11.
105. Schwaninger M, Ringleb P, Winter R, Kohl B, Fiehn W, Rieser PA, Walter-Sack I: Elevate plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia, 1999, 40, 345-350.
106. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH et al.: Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med, 1995, 332, 286-291.
107. Seligmann H, Potasman I, Weller B, Schwartz M, Prokocimer M: Phenytoin-folic acid interaction: a lesson to be learned. Clin Neuropharmacol, 1999, 22, 268-272.
108. Sener U, Zorlu Y, Karaguzel O, Ozdamar O, Coker I, Topbas M: Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, Vitamin B12, folic acid and Vitamin B6. Seizure, 2006, 15, 79-85.
109. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE: An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 2000, 41(Suppl. 1), S3-S9.
110. Soelberg Sřrensen P, Hammer M: Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. Eur J Clin Pharmacol, 1984, 26, 719-722.
111. Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, Topbas M: Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol. 2006, 21, 70-74.
112. Sözüer DT, Atakli D, Dogu O, Baybas S, Arpaci B: Serum lipids in epileptic children treated with carbamazepine and valproate. Eur J Pediatr, 1997, 186, 565-567.
113. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J: Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest, 1993, 91, 308-318.
114. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV et al.: A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA, 1992, 268, 877-881.
115. Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT: Methylation demand and homocysteine metabolism: effects of dietary provision of creatine and guanidinoacetate. Am J Physiol Endocrinol Metab, 2001, 281, 1095-1100.
116. Strandjord RE, Aanderud S, Myking OL, Johannessen SI: Influence of carbamazepine on serum thyroxine and triiodothyronine in patients with epilepsy. Acta Neurol Scand, 1981, 63, 111-121.
117. Strong JP, Zieske AW, Malcom GT: Lipoproteins and atherosclerosis in children: an early marriage? Nutr Metab Cardiovasc Dis, 2001, 11, 16-22.
118. Suzuki H, Yamazaki N, Suzuki Y, Hiraiwa M, Shimoda S, Mori K, Miyasaka M: Lowering effect of diphenylhydantoin on serum free thyroxine and thyroxine binding globulin. Acta Endocrinol, 1984, 105, 477-481
119. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA: Hyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation, 1997, 95, 1119-1121.
120. Tekgul H, Demir N, Gokben S: Serum lipid profile in children receiving anti-epileptic drug monotherapy: is it atherogenic? J Pediatr Endocrinol Metab, 2006, 19, 1151-1155.
121. Thambyrajah J, Townend JN: Homocysteine and atherothrombosis-mechanisms for injury. Eur Heart J, 2000, 21, 967-974.
122. Tümer L, Serdaroglu A, Hasanoglu A, Biberoglu G, Aksoy E: Plasma homocysteine and lipoprotein (a) levels as risk factors for atherosclerotic vascular disease in epileptic children taking anticonvulsants. Acta Paediatr, 2002, 91, 923-926.
123. Ueland PM, Refsum H: Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med, 1989, 114, 473-501.
124. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH: Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem, 1993, 39, 1764-1779.
125. Vainionpää LK, Mikkonen K, Rattya J, Knip M, Pakarinen AJ, Myllylä VV, Isojärvi JI: Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia, 2004, 45, 197-203.
126. Van Beynum IM, Smeitink JA, Heijer M, te Poele Pothoff MT, Blom HJ: Hyperhomocysteinemia: a risk factor for ischemic stroke in children. Circulation, 1999, 99, 2070-2072.
127. Van den Berg M, Boers GH, Franken DG, Blom HJ, Van Kamp GJ, Jakobs C, Rauwerda JA et al.: Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest, 1995, 25, 176-181.
128. Verrotti A, Basciani F, Domizio S, Sabatino G, Morgese G, Chiarelli F: Serum lipids and lipoproteins in patients treated with antiepileptic drugs. Pediatr Neurol, 1998, 19, 364-367.
129. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F: Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol, 2001, 25, 43-46.
130. Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F: Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health, 1997, 33, 242-245.
131. Verrotti A, Pascarella R, Trotta D, Giuva T, Morgese G, Chiarelli F: Hyperhomocysteinemia in children treated with sodium valproate and carbamazepine. Epilepsy Res, 2000, 41, 253-257.
132. Vilaseca MA, Monros E, Artuch R, Colome C, Farre C, Valls C, Cardo E et al.: Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C→T mutation of the methylenetetrahydrofolate reductase gene. Eur J Paediatr Neurol, 2000, 4, 269-277.
133. Voudris KA, Attilakos A, Katsarou E, Drakatos A, Dimou S, Mastroyianni S, Skardoutsou A et al.: Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res, 2006, 70, 211-217.
134. Wierzbicki AS: Homocysteine and cardiovascular disease: a review of the evidence. Diab Vase Dis Res, 2007, 4, 143-150.
135. Yamamoto M, Hara H, Adachi T: Effects of homocysteine on the binding of extracellular-superoxide digmutase to the endothelial cell surface. FEBS Lett, 2000, 486, 159-162.
136. Yilmaz E, Dosan Y, Gügöze MK, Güngör S: Serum lipid changes during anticonvulsive treatment serum lipids in epileptic children. Acta Neurol Belg, 2001, 101, 217-220.
137. Yoo JH, Hong SB: A common mutationin the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anti-convulsants. Metabolism, 1999, 48, 1047-1051.
138. Yüksel A, Aksoy T, Yalgin E: Effects of antiepileptics on serum thyroid hormones and hypothalamo-hypophysis axis in children. Pediatri Congress. Summary-Book, Antalya, 1992.
139. Yüksel A, Kartal A, Cenani A, Yalçin E: Serum thyroid hormones and pituitary response to thyrotropin-releasing hormone in epileptic children receiving anti-epileptic medication. Acta Paediatr Jpn, 1993, 35, 108-112.
140. Zhu SQ, Liu XM, Ruan XZ, Cai Z: Changes of thyroid hormone levels in epileptic patients. J Tongji Med Univ, 1994, 14, 119-123.